Eli Lilly's $1.54B Volume Crumbles to 48th Amid 1.06% Slide

On September 23, 2025, , ranking 48th in market activity. , underperforming broader market trends amid mixed sectoral momentum.

Recent developments highlight regulatory scrutiny intensifying for LLY as U.S. lawmakers launched an inquiry into its diabetes drug pricing strategies. The probe focuses on potential anticompetitive practices related to Trulicity and Mounjaro, . Analysts note this could trigger short-term volatility as investors weigh legal risks against long-term growth prospects in the diabetes therapeutic segment.

Separately, clinical data releases from mid-September showed marginal efficacy improvements in LLY’s oncology pipeline. While Phase III results for a breast cancer therapy met primary endpoints, the marginally better outcomes compared to existing treatments failed to generate strong market enthusiasm. This contrasts with earlier optimism for its , which remains on track for 2026 regulatory submission.

Back-testing parameters for the volume-based strategy require clarification of several operational details. The proposed approach—constructing a daily portfolio of 500 high-volume U.S. equities with equal weighting and one-day holding periods—depends on specific execution rules. Key variables include using prior-day closing volumes for sorting, entering positions at the next-day open, and assuming zero transaction costs. Performance evaluation will aggregate individual stock returns into a synthetic index to measure cumulative returns, maximum drawdowns, and risk-adjusted metrics like Sharpe ratios.